What Happened in Retatrutide Phase 2, the Middle Testing Stage?

What benefits and risks are already known?

People lost roughly 24% of their weight during Phase 2, the middle testing stage. Blood sugar improved in type 2 diabetes, and people with fatty liver disease lost liver fat.

Study staff watched health changes closely, including sickness and a rise in resting pulse. Retatrutide has no approval anywhere, so these findings aren't treatment that you can receive.

People using retatrutide on their own for research describe less hunger and rapid weight loss. Many also describe stomach trouble soon after starting, and some notice a quicker heartbeat.

Those accounts cannot show how likely harm is or who faces the greatest risk. Outside bottles also lack testing to check which drug is present, its amount and possible germs.

Larger study amounts raised pulse more, but the lasting effects on heart health remain unknown. Researchers still need answers about lost muscle and the weight people regain after treatment ends.

Published studies measured changes under medical supervision; outside users described their own experiences. Both raise concerns, but the outside accounts can't give you a measured chance of harm.

What have people using retatrutide on their own described?

People described these changes while using retatrutide for research without a study team's supervision. A controlled study, which compares treatment groups, hasn't checked the accounts or shown how often the changes occur.

Public discussions contain reports of both helpful changes and problems after using the drug. They don't give a reliable count of users, so your chance of each effect remains unknown.

Nobody watching these users established a safe amount for another person to take. Feeling better after a shot cannot prove the contents of the bottle were safe.

Which changes did people welcome?

Less interest in eating: People describe food taking up less of their thoughts during the day. Meals feel less tempting, without the same effort to resist eating.

Some compare that feeling with earlier medicines that also reduce hunger through hormone responses. Less hunger describes a feeling, rather than a measured improvement in your health.

Quick weight loss: People describe their weight falling faster than with medicines they tried before. Some notice the change within the first few weeks, but nobody checked those reports in a study.

Phase 2 studies also found large weight changes, which may sound similar to these experiences. That resemblance cannot establish how much an outside user lost or what caused the loss.

Less worry about meals: Some people feel calmer about food and describe a better mood. Those feelings are mentioned less often than the loss of hunger in public discussions.

The users themselves suggest GLP-1, a hormone linked with hunger, might affect craving and enjoyment. Earlier research linked that hormone with seeking less food, but the cause in these people isn't known.

What changes prompted mixed reactions?

Feeling warmer: People describe mild warmth, red cheeks or sweating during ordinary daily tasks. Some blame glucagon, a hormone that makes the body burn calories, for the warmth.

Calorie burning produces heat, but those users are guessing about what caused their warmth. Warmth alone cannot establish lasting weight loss or improved health for you.

Muscles feeling softer: Some people worry about losing muscle when their weight drops quickly. Their accounts don't measure the muscle lost or show how strength changed.

Phase 2 tests found loss of tissue besides fat, including muscle, as weight fell. Fat loss was greater, but those tests can't tell you how much strength you'd lose.

Which problems followed the shots?

Sickness: An upset stomach was often described soon after starting or increasing the amount. Reports placed the worst sickness 4-8 hours following a shot, with the trouble easing later.

Many describe the first weeks as harder, though the accounts differ from person to person. Study volunteers also had more stomach trouble when amounts were larger, adding weight to that concern.

A faster heartbeat: Some users saw their resting pulse increase soon after an injection. Their watches recorded rises of 5-15 beats per minute above their usual resting readings.

Phase 2 studies also measured a faster pulse, with greater rises at larger amounts. A pulse watch reading can't establish whether the increase is safe for your heart.

Bad-smelling burps: People describe burps that smell like rotten eggs and come and go. Some think slower movement of food through the stomach explains the smell, but the cause isn't checked.

Tiredness: Early users describe needing more sleep, legs feeling heavy and thoughts becoming less clear. Eating less is the cause they suggest, rather than an explanation checked through research.

Constipation: Some people passed stools less often after eating less and noticing slower digestion. They link the change with GLP-1's effect on the gut, but the accounts can't establish the cause.

Red or itchy skin: Mild redness or itching appeared around the skin where some people had injected retatrutide. The skin often cleared within 24-48 hours; similar problems affected about 8% during Phase 2 testing.

Poor sleep: A few accounts describe wakeful nights or trouble getting to sleep after starting. Sleep complaints appear less often, and nobody has established why those people's sleep changed.

Which safety concerns could matter for your health?

Stomach sickness and a rise in resting pulse were measured; outside bottles add supply risks. The published papers named beside each finding explain what was checked in people.

Could an outside bottle contain something unsafe?

Outside supplies lack approval and checks establishing the drug, amount and absence of germs ^[1][6]. The bottle may hold another drug or a different amount from the label.

Tests of similar research supplies found damaged protein parts and sometimes an entirely different drug. An injection carrying germs may cause an infection that reaches the bloodstream.

In 2025, the FDA sent retatrutide sellers more than 50 letters warning about unlawful sales. The letters don't test your bottle, but a seller's assurance cannot replace supply checks.

How often did stomach sickness make people stop?

Phase 2 studies reported sickness, vomiting, constipation and diarrhea, sometimes severe enough to stop treatment ^[1][2][4]. In the 48-week weight study, up to 45% felt sick at the largest amount.

At that amount, 18% stopped, so the trouble wasn't mild for everyone taking part. GLP-1, a hormone that reduces hunger, also slows food moving through the stomach and gut.

Study staff could spot severe trouble and check people while amounts were being raised. Without those checks, vomiting and diarrhea may cause too much loss of water and body salts.

How much faster did the heart beat?

Resting pulse rose more at larger retatrutide amounts in the studies ^[1][7][9]. At the highest amounts during Phase 2, pulse rose by about 5-7 beats per minute.

The rise peaked around 24 weeks, with glucagon's action helping explain the quicker heartbeat. Heart testing still needs to establish whether a lasting pulse increase harms people's health.

People with heart disease, an uneven heartbeat or an already fast pulse face unanswered risks. Early studies don't tell you how safe outside use would be for those people.

Could other diabetes medicines make blood sugar fall too far?

Blood sugar may fall dangerously when retatrutide is added to insulin treatment or some diabetes pills ^[2][10]. Those medicines can add to retatrutide's effect of helping the body release insulin.

Two hormone responses prompt insulin release as sugar increases, helping bring sugar levels down. Extra insulin from another treatment can make that fall too great for your body.

Staff lowered insulin amounts for some people already taking insulin during Phase 2 testing. Outside a study, dangerously low sugar might go unnoticed without those checks and treatment changes.

Could muscle loss leave an older person weaker?

In 2025, a type 2 diabetes study reported less fat along with tissue loss that included muscle ^[11]. Compared with older surgery findings, a greater share of the lost weight was fat.

Losing muscle can still matter greatly when age has already made your muscles weaker. Separate research linked protein in food and strength exercise with less muscle loss during GLP-1 drug use.

Which risks need longer follow-up?

In mid-2026, TRIUMPH remained unfinished, as did the studies checking heart and kidney health ^[7][9]. Lasting harm and protection from heart and kidney illness remain unknown rather than assured benefits.

Related drug findings from Phase 2 suggest stopping treatment may be followed by substantial weight regain. Longer kidney testing must also establish safety, leaving questions about long use without medical supervision.